2019 IDSA
Guidelines for Community Acquired Pneumonia in Adults: To HCAP, we just say
fare thee well
by Jon-Emile
S. Kenny
New
guidelines from the American Thoracic Society/Infectious Disease Society of
America
Background
The last
American Thoracic Society/Infectious Disease Society of America [ATS/IDSA]
guidelines on community acquired pneumonia [CAP] were published in 2007; it
seems hard to remember the world at that time – free from the tweeting of
medical information, free from the tweeting of world leaders. Is 2019
better for everyone? Worse? For some?
The 2019 inception of the ATS/IDSA guidelines for CAP reserves
a more pragmatic approach than its screed-like predecessor – clearly defining
16 high-yield clinical questions and answering them under the direction of the
PICO framework. Critically, the current recommendations make clear that:
“This guideline focuses on
patients in the United States who have not recently completed foreign travel….
on adults who do not have an immunocompromising condition, such as inherited or
acquired immune deficiency or drug-induced neutropenia, including patients
actively receiving cancer chemotherapy, patients infected with HIV with
suppressed CD4 counts, and solid organ or bone marrow transplant recipients.”
Accordingly,
and as mentioned in the 2016 update on hospital-acquired and ventilator-associated pneumonia,
guidelines remain guidelines.
They are not sacrosanct; they needn’t be followed without falter in all
patients, always; clinical judgement and individual patient characteristics are
also guiding principles. In my humble opinion, the only deontological
imperative is that you are informed and the current IDSA
CAP guidelines are an excellent fund of rational, practical information.